Related Experiment Video
Updated: Sep 9, 2025
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
Prognostic Performance of the Residual Cancer Burden Index With Respect to Molecular Breast Cancer Subtypes
Emanuelle Narciso Alvarez Valente1, Anke Bergman1, Marcelo Adeodato Belloa1
1Instituto Nacional do Câncer (INCA), Master Degree, Rio de Janeiro, Brazil.
Objective:
The use of neoadjuvant chemotherapy (NAC) has improved outcomes in breast cancer (BC). The residual cancer burden index (RCB) predicts prognosis. This study evaluated RCB as a prognosticator in BC subtypes treated with NAC.
Materials And Methods:
A retrospective cohort of BC patients was analyzed. Five-year distant recurrence-free survival (DRFS), disease-free survival (DFS), and overall survival (OS) were analyzed. Statistical analyses included descriptive statistics, ANOVA, chi-square test, Fisher's exact test, Kaplan-Meier curves, Log-Rank test, and Cox regression.
Results:
Among 562 women, RCB correlated with BC subtypes and predicted worse DRFS, DFS, and OS. In stratified analyses by molecular subtype, the association was significant only for luminal B and triple-negative subtypes, with inconsistent findings for luminal A and human epidermal growth factor type 2-overexpressed subtypes.
Conclusion:
The RCB index was shown to be a prognostic marker in BC in a Brazilian population with BC. Significant associations were found only for the luminal B and triple negative subtypes. Further research is required to investigate the prognostic utility of RCB in other larger populations.
More Related Videos
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
07:13Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
Published on: April 18, 2025
